ELAVL1 and glioblastoma: Our work provides a new approach for the elimination of the TREM1+-myeloid-derived microenvironment in glioblastomas by using an inhibitor of HuR dimerization SRI42127, which suppressed TREM1 expression, activation, and TREM1-dependent directional myeloid-cell migration and fusion with glioblastoma cells.